Magenta Therapeutics, Inc. (MGTA)
Stock Price:
$6.69 USD
-0.06 (-0.89%)
Updated Oct 27, 2020 1:41 PM EDT - Market open
Key Info
| Market Cap |
322.81M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-83.32M |
| Shares Out |
48.25M |
| EPS (ttm) |
-2.12 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$6.69 |
| Previous Close |
$6.75 |
| Change ($) |
-0.06 |
| Change (%) |
-0.89% |
| Day's Open |
6.74 |
| Day's Range |
6.57 - 6.84 |
| Day's Volume |
62,710 |
| 52-Week Range |
5.76 - 16.19 |
More Stats
| Market Cap |
322.81M |
| Enterprise Value |
144.53M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
48.25M |
| Float |
29.18M |
| EPS (basic) |
-2.13 |
| EPS (diluted) |
-2.12 |
| FCF / Share |
-1.61 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.60M |
| Short Ratio |
9.39 |
| Short % of Float |
5.50% |
| Beta |
2.57 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.96 |
| Revenue |
n/a |
| Operating Income |
-88.54M |
| Net Income |
-83.32M |
| Free Cash Flow |
-63.85M |
| Net Cash |
178.28M |
| Net Cash / Share |
3.69 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-28.66% |
| ROE |
-47.14% |
| ROIC |
-129.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$16.67*
(149.18% upside)
Low
13.0
Current: $6.69
High
22.0
Target: 16.67
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -82.97 | -59.96 | -35.73 | -9.27 |
| Net Income | -76.77 | -57.52 | -35.49 | -9.43 |
| Shares Outstanding | 37.01 | 18.39 | 1.86 | 0.15 |
| Earnings Per Share | -2.07 | -3.13 | -19.12 | -65.15 |
| Operating Cash Flow | -57.10 | -41.89 | -22.26 | -6.53 |
| Capital Expenditures | -3.06 | -7.66 | -2.20 | -0.14 |
| Free Cash Flow | -60.16 | -49.55 | -24.46 | -6.67 |
| Cash & Equivalents | 148 | 144 | 51.57 | 4.54 |
| Net Cash / Debt | 148 | 144 | 51.57 | 4.54 |
| Assets | 162 | 157 | 54.46 | 11.34 |
| Liabilities | 20.32 | 11.67 | 4.14 | 20.22 |
| Book Value | 141 | 146 | -42.12 | -8.87 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Magenta Therapeutics, Inc. |
| Country |
United States |
| Employees |
72 |
| CEO |
Jason Gardner |
Stock Information
| Ticker Symbol |
MGTA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MGTA |
Description
Magenta Therapeutics, a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. Thecompany is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. It has a has a research and clinical collaboration agreement with AVROBIO, Inc.to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.